The MDS results for the ΔELREA mutation are also consistent with the effects of compounds (Fig 10A–10C) that inhibit EGFR mutant cell lines [49–51]: inhibitors recognizing the active conformation are more effective against the ΔELREA mutant in lung cancer cell lines as compared to cell lines expressing wild-type EGFR. This evidence concerns the gene EGFR and lung cancer.